{"adverse_reactions":["ADVERSE REACTIONS Adverse reactions from topical use of ALOQUIN is expected to be low when used as directed, due to low concentration of Iodoquinol present in this topical gel. To achieve the equivalent of a common daily oral dose of nearly 2,000 mg Iodoquinol, one will need to use more than 2 full tubes of 60 g ALOQUIN in a single application. Adverse reactions from oral form of Iodoquinol (nearly 2,000 mg daily) have been reported: various forms of skin eruptions, hives, itching, nausea, vomiting, abdominal cramps, diarrhea, anusitis, fever, chills, headache, vertigo and enlargement of thyroid."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenisis and Impairment of Fertility Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol."],"contraindications":["CONTRAINDICATIONS ALOQUIN is contraindicated in those patients with a history of hypersensitivity to any components of the preparation."],"description":["DESCRIPTION Each gram of ALOQUIN contains 1.25% (12.5 mg) Iodoquinol and 1% (10mg) Aloe Polysaccharides. Other ingredients: Purified Water, Carbomer 980, Magnesium Aluminum Silicate, PEG-20 Methyl Glucose Ether, Aminomethyl Propanol 95, Biopeptide, Propylene Glycol, Glycerine, SDA Alcohol 40 B, Benzyl Alcohol, Trolamine, FD&C Blue #1 and D&C Yellow #10. Iodoquinol Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C 9 H 5 I 2 NO) and is represented by the following structural formula: Aloe Polysaccharide The Aloe Polysaccharide in ALOQUIN is a patented mixture of acetylated mannan aloe polysaccharide. Each purified acetylated mannan polysaccharide of specific molecular weight range and average is composed of the same repeating subunits shown below (where m is mannose, n is galactose and p is glucose monomers): Chemical Structure Chemical Structure"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Apply to affected areas 3-4 times daily or as directed by a physician. Follow your physician's directions regarding length of treatment after symptoms resolve."],"effective_time":"20091007","how_supplied":["HOW SUPPLIED NDC # 68040-706-16 60 gram gel tube NDC # 68040-706-01 1 gram gel individual pack NDC # 68040-706-08 10-count carton of 1 gram gel sample packs - not for resale Each 1 gram gel pack contains multiple doses depending on the surface area treated. STORAGE Store at room temperature 15°-30°C (59°-86°F). Keep tightly closed."],"how_supplied_table":["<table width=\"60%\"> <col width=\"50%\" align=\"left\" valign=\"top\"/> <col width=\"50%\" align=\"left\" valign=\"top\"/> <tbody> <tr styleCode=\"Toprule\"> <td>NDC # 68040-706-16</td> <td>60 gram gel tube</td> </tr> <tr> <td>NDC # 68040-706-01</td> <td>1 gram gel individual pack</td> </tr> <tr styleCode=\"Botrule\"> <td>NDC # 68040-706-08</td> <td>10-count carton of 1 gram gel sample packs - not for resale</td> </tr> </tbody> </table>"],"id":"610958fb-6663-430c-854a-1b7f36c8c80a","indications_and_usage":["INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: \"Possibly\" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation."],"nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOQUIN is administered to a nursing woman."],"openfda":{},"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 60g Carton NDC 68040-706-16 AloQuin ™ GEL 1.25% iodoquinol • 1% aloe polysaccharides Contains Moisturizers • For Dermatological Use Only Rx Only Biopeptide Aloe Complex™ Deeper Penetration • Patented Formula Net Wt. 60g PRINCIPAL DISPLAY PANEL - 60g Carton"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients under the age of 12 have not been established."],"pregnancy":["Pregnancy Category C Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed."],"set_id":"179b8b28-c76b-4686-a04c-6b2f90056de9","spl_product_data_elements":["Aloquin Aloe Vera Leaf and Iodoquinol Aloe Vera Leaf Aloe Vera Leaf Iodoquinol Iodoquinol"],"spl_unclassified_section":["Prescribing Information","Rx ONLY www.aloquin.com Manufactured for: Primus Pharmaceuticals, Inc. Scottsdale, AZ 85251 www.primusrx.com Manufactured by: Sonar Products, Inc. Carlstadt, NJ 07072 U.S. Patents #6,436,679; #6,271,214; #6,133,440; #5,925,357; #5,902,796; #5,708,038; #5,703,060; #5,468,737; other patents pending. ©2009 Primus Pharmaceuticals, Inc. All rights reserved. ISS.0309 #15905"],"storage_and_handling":["STORAGE Store at room temperature 15°-30°C (59°-86°F). Keep tightly closed."],"teratogenic_effects":["Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed."],"version":"1","warnings_and_cautions":["WARNINGS AND PRECAUTIONS For external use only. Keep away from eyes. If irritation develops, the use of ALOQUIN should be discontinued and appropriate therapy instituted. Some discoloration of the skin, hair and fabrics may occur, but can be removed with normal cleansing and laundry. Not intended for use on infants or under diapers or occlusive dressings. Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if Iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy. Keep out of reach of children. Carcinogenesis, Mutagenisis and Impairment of Fertility Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol. Pregnancy Category C Animal reproductive studies have not been conducted with ALOQUIN. It is not known whether ALOQUIN can cause fetal harm when administered to pregnant women or can affect reproductive capacity. ALOQUIN should be given to pregnant women only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOQUIN is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients under the age of 12 have not been established."]}